^
    2d
    HPV genotyping in head and neck cancer: Insights from a Colombian cohort. (PubMed, Braz J Otorhinolaryngol)
    This study demonstrates a high prevalence of HPV, predominantly HPV-16, in oropharyngeal carcinomas compared with other head and neck sites in our cohort. These results provide baseline data for Colombia and highlight the need for multicenter studies including more heterogeneous populations to guide future prevention and control strategies.
    Journal
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A)
    2d
    Discovery and validation of a prognostic SPP1/PLAU signature in HPV-negative oropharyngeal squamous cell carcinoma. (PubMed, BMC Med Genomics)
    The SPP1/PLAU dual-gene signature is a robust and independent prognostic biomarker for OPSCC, with particular clinical utility for stratifying high-risk HPV-negative patients.
    Journal
    |
    SPP1 (Secreted Phosphoprotein 1) • PLAU (Plasminogen Activator)
    6d
    Radiotherapy Dose De-escalation in HPV-Associated Cancers of the Oropharynx (clinicaltrials.gov)
    P=N/A, N=120, Active, not recruiting, Duke University | Recruiting --> Active, not recruiting | Trial completion date: Jan 2028 --> Jul 2028 | Trial primary completion date: Jan 2028 --> Jul 2028
    Enrollment closed • Trial completion date • Trial primary completion date
    6d
    Prognostic Impact of miR-34a in Head and Neck Squamous Cell Carcinoma: A Systematic Review with Meta-Analysis and Trial Sequential Analysis. (PubMed, Int J Mol Sci)
    Overall, low tumor miR-34a expression appears to be associated with poorer OS, but the evidence is limited by retrospective design, small sample size, and marked heterogeneity. miR-34a is a promising biomarker for prognostic stratification in HNSCC, yet larger, prospective, site-specific studies with standardized assays, pre-defined cut-offs, and appropriate adjustment for HPV status and clinical covariates are required before clinical implementation can be recommended.
    Clinical • Retrospective data • Review • Journal
    |
    MIR34A (MicroRNA 34a-5p)
    6d
    Detection of recurrence of HPV-driven oropharyngeal cancer by HPV cell-free DNA. (PubMed, Sci Rep)
    Monitoring HPV cfDNA levels may identify patients at risk of recurrence early, thereby potentially facilitating timely intervention. Studies with more participants are needed to establish a solid evidence base for surveillance protocols that incorporate HPV cfDNA.
    Journal
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A)
    10d
    Evaluating a Decreased Dose of Radiation Therapy to the Elective Neck for the Treatment of HPV-Related Oropharyngeal Cancer, ENLIGHT Trial (clinicaltrials.gov)
    P2, N=100, Recruiting, Northwestern University | Not yet recruiting --> Recruiting | Initiation date: Mar 2026 --> Dec 2025
    Enrollment open • Trial initiation date
    10d
    CPI: Pharmacokinetic Study of Pembrolizumab and Its Impact on Immunity and the Tumor Microenvironment, Which May Explain the Efficacy of Post-immunotherapy Chemotherapy. (clinicaltrials.gov)
    P4, N=110, Not yet recruiting, Centre Antoine Lacassagne
    New P4 trial
    |
    Keytruda (pembrolizumab)
    10d
    ROMA LA-OPSCC2: Role of Microbiome as a Biomarkers in Locoregionally-Advanced Oropharyngeal Squamous Cell Carcinoma 2 (clinicaltrials.gov)
    P=N/A, N=30, Completed, University Health Network, Toronto | Active, not recruiting --> Completed | Trial completion date: Mar 2026 --> Sep 2025 | Trial primary completion date: Jan 2026 --> Sep 2025
    Trial completion • Trial completion date • Trial primary completion date
    13d
    RADIO-PBM: Evaluation of Two Methods of Administration of Photobiomodulation in the Context of the Prevention and Treatment of Mucositis Induced by Radiotherapy, During the Treatment of Head and Neck Cancers (clinicaltrials.gov)
    P=N/A, N=60, Not yet recruiting, Centre Paul Strauss | Trial completion date: May 2026 --> Nov 2029 | Trial primary completion date: May 2026 --> Nov 2029
    Trial completion date • Trial primary completion date
    13d
    A Study of Neurocognitive Tests and Questionnaires for People With Head and Neck Cancer Who Are Undergoing Radiation Therapy (clinicaltrials.gov)
    P=N/A, N=60, Recruiting, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Recruiting
    Enrollment open
    14d
    Phase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal Cancer Followed by De-Intensified Radiation Compared With Standard Chemoradiation (clinicaltrials.gov)
    P2, N=70, Not yet recruiting, ImmunityBio, Inc.
    New P2 trial
    |
    Avastin (bevacizumab) • cisplatin • albumin-bound paclitaxel • Anktiva (nogapendekin alfa inbakicept-pmln) • PD-L1.t-haNK
    14d
    Detection of human papillomavirus infection in oral mucosal diseases: A single-center study. (PubMed, JADA Found Sci)
    The highest rate of HPV infection was in male patients, patients with OL and OLP, and conditions affecting the buccal mucosa. Larger studies are needed to elucidate the role of HPV in the development of these conditions.
    Journal
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A)